Understanding the PRoFESS Study for Secondary Stroke Prevention (Q37477420)

20 August 2017

title

Understanding the PRoFESS Study for Secondary Stroke Prevention (English)

1 reference

20 August 2017

Michael J Schneck

1

1 reference

20 August 2017

language of work or name

1 reference

1 June 2009

1 reference

Current treatment options in cardiovascular medicine

20 August 2017

published in

1 reference

20 August 2017

volume

11

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

221-231

1 reference

Good enough: a primer on the analysis and interpretation of noninferiority trials

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11936-009-0023-7

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

12 December 2020

Prevention of stroke in patients with hypertension

1 reference

12 December 2020

Randomized clinical trial design for assessing noninferiority when superiority is expected

1 reference

12 December 2020

Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

12 December 2020

Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy

1 reference

12 December 2020

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

1 reference

12 December 2020

Controlling the type 1 error rate in non-inferiority trials.

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group

1 reference

12 December 2020

Assessing non-inferiority: a combination approach

1 reference

12 December 2020

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

12 December 2020

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

12 December 2020

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

1 reference

12 December 2020

Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients?

1 reference

12 December 2020

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

12 December 2020

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

12 December 2020

Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies

1 reference

12 December 2020

From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study

1 reference

12 December 2020

1 reference

12 December 2020

Emerging therapies: ESPRIT

1 reference

12 December 2020

Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease

1 reference

12 December 2020

Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease

1 reference

12 December 2020

Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials

1 reference

12 December 2020

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

12 December 2020

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

12 December 2020

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

12 December 2020

Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke

1 reference

12 December 2020

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

12 December 2020

Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?

1 reference

12 December 2020

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events

1 reference

12 December 2020

Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view

1 reference

12 December 2020

Stroke prevention--insights from incoherence

1 reference

12 December 2020

Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2

1 reference

12 December 2020

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

12 December 2020

Dipyridamole plus aspirin in cerebrovascular disease

1 reference

12 December 2020

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

12 December 2020

10.1007/S11936-009-0023-7

Identifiers

DOI

1 reference

20 August 2017

1 reference